Liraglutide is a GLP-1 receptor agonist, a peptide analogue of the natural GLP-1 hormone. It is an approved prescription medicine sold as Victoza for type 2 diabetes and Saxenda for weight management, given as a once-daily subcutaneous injection under medical supervision.

How does liraglutide work?

It activates GLP-1 receptors to enhance glucose-dependent insulin secretion, which lowers blood sugar mainly when glucose is high. It also slows gastric emptying and acts on central appetite pathways, reducing food intake and supporting weight loss.

Is liraglutide FDA-approved?

Yes. Liraglutide is an approved prescription medicine for type 2 diabetes (Victoza) and for chronic weight management (Saxenda) in various jurisdictions. It is prescription-only and not intended for unsupervised or research-market use.

What does the research say about liraglutide?

Liraglutide is backed by strong human clinical trial evidence and regulatory approval for improving blood glucose control and producing modest, sustained weight loss. Its pharmacology is also extensively characterised in preclinical animal models.

What are the side effects of liraglutide?

Commonly reported side effects include nausea and other gastrointestinal effects, particularly early in treatment. Because it is a prescription medicine with additional warnings that vary by region, patients should always consult the approved prescribing information and a healthcare provider.

Is liraglutide safe to use?

Liraglutide can be used safely when prescribed and monitored by a qualified healthcare professional according to its approved indications. It is a genuine medicine with real physiological effects and risks, so it should never be used without medical supervision.

How does liraglutide differ from newer GLP-1 drugs like semaglutide?

Liraglutide is a first-generation GLP-1 receptor agonist designed for once-daily dosing, with a half-life in the range of roughly half a day. Later agents such as semaglutide were engineered for a much longer half-life, allowing once-weekly administration. This is a factual comparison of pharmacology, not a recommendation to use either — both are prescription medicines used under medical supervision.

Why does liraglutide need daily administration while some GLP-1 drugs are weekly?

Native GLP-1 is broken down within minutes. Liraglutide's fatty-acid modification lets it bind albumin and resist rapid degradation, stretching its duration to about once-daily. It does not reach the extended half-life of weekly successors, which is a structural design difference rather than a measure of effectiveness.

Is 'liraglutide' the same thing as Victoza and Saxenda?

Yes — liraglutide is the active compound, while Victoza and Saxenda are two brand names for it approved at different doses and for different indications (diabetes versus weight management). They are the same molecule marketed under different labels, and all are prescription-only medicines.

Where can I buy Liraglutide and compare vendors?

Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Metabolic

Buy Liraglutide – Vendors, Prices, Testing and Evidence

Buy Liraglutide

Also known as: Victoza · Saxenda

Evidence grade A — Approved / StrongRisk flag

Short answer

A daily GLP-1 receptor agonist approved for diabetes and weight management. Informational only — not a source or promotion.

Where can you buy Liraglutide?

No peptide-specific vendor offer is currently verified. The vendor catalogue link is provided for discovery only and does not assert availability.

What is known?

Liraglutide is a GLP-1 receptor agonist and an approved prescription medicine used under medical supervision.

What is not established?

Strong clinical trial evidence and regulatory approval for glycemic control and weight loss.

Safety

A prescription medicine that must be used under medical supervision, with a prescribing information document that lists its risks in full. Research-market material is not the licensed product: it is not quality-assured, not dispensed by a pharmacist, and carries no prescribing information. Obtaining or using it without a prescription is unlawful in many countries.

Regulatory status

Approved prescription medicine for type 2 diabetes and weight management. Prescription-only; not for unsupervised research-market use.

Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.

Regulatory or safety concern: This substance may be unapproved for human use, affect the hormonal system, or be subject to regulator or anti-doping restrictions. Check the cited evidence and rules in your jurisdiction.

Vendor comparison

Buy Liraglutide: compare vendors

The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

What is it?

Liraglutide is a GLP-1 receptor agonist and an approved prescription medicine used under medical supervision.

Research and evidence

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist and an approved prescription medicine marketed under the brand names Victoza (for type 2 diabetes) and Saxenda (for weight management). Structurally an acylated analogue of the human GLP-1 hormone, it is designed for once-daily subcutaneous administration and belongs to the metabolic class of peptide therapeutics. Unlike many compounds catalogued in research contexts, liraglutide is a fully approved, regulated medication with an established clinical file, meaning it must be prescribed and used under medical supervision rather than sourced or self-administered.

Liraglutide is studied and prescribed because of two well-characterised actions. First, as a GLP-1 receptor agonist it enhances glucose-dependent insulin secretion, which lowers blood sugar primarily when glucose is elevated, an effect that helps limit hypoglycaemia risk compared with some older diabetes drugs. Second, it slows gastric emptying and acts on central appetite-regulating pathways, which reduces food intake and supports weight loss. These mechanisms underpin its dual regulatory approvals for glycaemic control in type 2 diabetes and for chronic weight management in eligible patients.

The evidence picture for liraglutide is unusually strong for a peptide: it rests on large randomised controlled trials and formal regulatory review, rather than the preclinical or anecdotal data that characterise many research peptides. Human clinical evidence supports meaningful improvements in blood glucose control and modest, sustained weight loss, and its pharmacology has been extensively characterised in preclinical animal models. That said, liraglutide is a real medicine with real effects and risks. It carries documented gastrointestinal side effects and warnings that vary by jurisdiction, and its use should always be guided by a qualified healthcare professional working from the approved prescribing information. peptides.cx presents this information for educational reference only and is not the seller; it is not medical advice, and where a shop link appears it is labelled advertising rather than a recommendation to use liraglutide. As a prescription-only medicine it lawfully requires a prescription and clinical supervision, and obtaining it without them is unlawful in many countries and can be dangerous.

Evidence grade: A

Strong clinical trial evidence and regulatory approval for glycemic control and weight loss. Extensively characterised in preclinical models.

Human evidence

Strong clinical trial evidence and regulatory approval for glycemic control and weight loss.

Animal and preclinical evidence

Extensively characterised in preclinical models.

Proposed mechanisms

GLP-1 receptor agonism enhancing glucose-dependent insulin secretion
Slowed gastric emptying and central appetite regulation

Safety concerns and known side effects

Nausea
Gastrointestinal effects
See approved prescribing information

Regulatory status

Approved prescription medicine for type 2 diabetes and weight management. Prescription-only; not for unsupervised research-market use.

Liraglutide research timeline

1980s
Glucagon-like peptide-1 (GLP-1) is characterised as an incretin hormone, establishing the biological target that liraglutide would later engage.
1990s
Researchers at Novo Nordisk engineer liraglutide by attaching a fatty-acid chain to a GLP-1 backbone, promoting albumin binding to extend its short native half-life toward once-daily use.
2000s
A programme of clinical trials evaluates liraglutide for glycemic control in type 2 diabetes, supporting its regulatory dossiers.
2009-2010
Liraglutide is approved for type 2 diabetes under the brand Victoza, first in the EU (2009) and then by the US FDA (2010).
mid-2010s
A higher-dose formulation is approved for chronic weight management under the brand Saxenda after dedicated obesity trials.
early 2020s
Liraglutide is increasingly viewed as a first-generation daily GLP-1 agonist as longer-acting weekly successors such as semaglutide reshape the field.

Frequently asked questions about Liraglutide

What is liraglutide?: Liraglutide is a GLP-1 receptor agonist, a peptide analogue of the natural GLP-1 hormone. It is an approved prescription medicine sold as Victoza for type 2 diabetes and Saxenda for weight management, given as a once-daily subcutaneous injection under medical supervision.
How does liraglutide work?: It activates GLP-1 receptors to enhance glucose-dependent insulin secretion, which lowers blood sugar mainly when glucose is high. It also slows gastric emptying and acts on central appetite pathways, reducing food intake and supporting weight loss.
Is liraglutide FDA-approved?: Yes. Liraglutide is an approved prescription medicine for type 2 diabetes (Victoza) and for chronic weight management (Saxenda) in various jurisdictions. It is prescription-only and not intended for unsupervised or research-market use.
What does the research say about liraglutide?: Liraglutide is backed by strong human clinical trial evidence and regulatory approval for improving blood glucose control and producing modest, sustained weight loss. Its pharmacology is also extensively characterised in preclinical animal models.
What are the side effects of liraglutide?: Commonly reported side effects include nausea and other gastrointestinal effects, particularly early in treatment. Because it is a prescription medicine with additional warnings that vary by region, patients should always consult the approved prescribing information and a healthcare provider.
Is liraglutide safe to use?: Liraglutide can be used safely when prescribed and monitored by a qualified healthcare professional according to its approved indications. It is a genuine medicine with real physiological effects and risks, so it should never be used without medical supervision.
How does liraglutide differ from newer GLP-1 drugs like semaglutide?: Liraglutide is a first-generation GLP-1 receptor agonist designed for once-daily dosing, with a half-life in the range of roughly half a day. Later agents such as semaglutide were engineered for a much longer half-life, allowing once-weekly administration. This is a factual comparison of pharmacology, not a recommendation to use either — both are prescription medicines used under medical supervision.
Why does liraglutide need daily administration while some GLP-1 drugs are weekly?: Native GLP-1 is broken down within minutes. Liraglutide's fatty-acid modification lets it bind albumin and resist rapid degradation, stretching its duration to about once-daily. It does not reach the extended half-life of weekly successors, which is a structural design difference rather than a measure of effectiveness.
Is 'liraglutide' the same thing as Victoza and Saxenda?: Yes — liraglutide is the active compound, while Victoza and Saxenda are two brand names for it approved at different doses and for different indications (diabetes versus weight management). They are the same molecule marketed under different labels, and all are prescription-only medicines.
Where can I buy Liraglutide and compare vendors?: Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Common discussion areas

Regulatory statusApproved use only

Sources

Editorial review and transparency

Written by: peptides.cx Editorial Team
Scientific reviewer: No named medical reviewer is currently assigned
Last editorial review: June 1, 2026
Last vendor check: July 18, 2026
Review method: Source review, claim verification, vendor-data separation and regulatory-context review.
Commercial disclosure and conflicts: Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.

Editorial policy →Evidence grade →Vendor methodology →

Related on peptides.cx

Library →Vendor quality checklist →Safety →Affiliate code: PEPTIDES10